我国医药产业规模位居全球第二位 研创新药数目达全球30%左右

Core Insights - The National Medical Products Administration (NMPA) is focused on ensuring drug safety and supporting high-quality development of the pharmaceutical industry during the 14th Five-Year Plan period [1] - China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs under research being developed in the country [1] - Since the beginning of the 14th Five-Year Plan, 387 pediatric drugs and 147 rare disease drugs have been approved for market, effectively meeting the medication needs of key populations [1]